Lantheus Inks Isotope Deal with JHS as Ben Venue Exits the Picture

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

As Ben Venue Laboratories continues to withdraw from the contract manufacturing services market, its client, Lantheus Medical Imaging, has found a new partner for the manufacture of a pair of contrast agents.

Jubilant HollisterSteir brokered a five-year-deal with Lantheus to make Cardiolite and Neurolite, two technetium-based isotopes used in SPECT imaging. The arrangement carries the option of a five-year renewal after its expiry.

The two companies have a similar deal in place for the manufacture of the ultrasound agent, Definity Vial. Lantheus is already looking to find additional partners with which to manufacture Cardiolite, Neurolite, and Definity by end-2013.